A First-in-human Study of the Effects of SRP-1005 in Participants With Huntington's Disease
Sarepta Therapeutics, Inc.
Phase 1 study testing SRP-1005 in Huntington's disease.
RecruitingPhase 1DrugClinicalTrials.govTreatment trial
Recruiting in: Auckland, Christchurch, New Zealand
Preparing a short plain-English summary.
